alexa Genomics In Bioavailability And Bioequivalence
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Wolfgang Sadee
Accepted Abstracts: J Bioequiv Availab
DOI: 10.4172/0975-0851.S1.019
R apid advances in genomics technologies exert profound impact on the biomedical sciences. The main goal of the pharmaceutical sciences is to understand individual differences in drug response and toxicity, as a foundation for developing and guiding therapy for each patient. Bioavailability and bioequivalence represent important factors in the design of optimal drug therapy. Both genetic variants and epigenetic factors, and interplay between them, determine a portion of inter-individual variability, with expression of drug metabolizing enzymes (DMEs) and transporters playing a key role. A number of genetic variants have already been incorporated into pharmacogenetic biomarker tests, but the vast majority of (epi) genetic variability remains hidden. We have implemented gene-by-gene and genome-wide methods to search for pharmacologically relevant variants and regulatory processes, using next generation sequencing of DNA and RNA (RNAseq of coding and non-coding RNAs). A survey of DME and transporter expression reveals distinct expression profiles in various tissues, and the presence of multiple RNA transcripts at each gene locus (such as splice variants). Broad understanding of the regulation of DMEs and transporters has the potential to guide drug development and clinical application
Wolfgang Sadee is Professor of Pharmacology, Director of the OSU College of Medicine Center for Pharmacogenomics, and member of the NIGMS Pharmacogenomics Research Network. He had served on the pharmacy faculties of USC and UCSF until 2002. His research focuses on pharmacogenomics to discover genetic variants affecting drug response and develop biomarkers for optimizing an individual?s therapy. He has published over 350 research papers, chapters, and monographs, served as founding editor of Pharmaceutical Research and The AAPS Journal, and received several awards, including the AAPS Distinguished Scientist Award
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version